Pancreatic Cancer Research

ResearcherJilin UniversityActive in the last 2 years

Yahui Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4018-5404; OpenAlex author ID A5100375495. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 11

  1. Precision medicine advances in pancreatic cancer driven by genomic and molecular alterations. Last author DOI 10.4251/wjgo.v17.i11.111264↗
  2. Retraction notice to "LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p" [Biomed. Pharmacother. 114 (2019) 108862]. Last author DOI 10.1016/j.biopha.2024.116188↗
  3. Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.5210↗
  4. Long-term outcome and prognostic factors of pancreatic ductal adenocarcinoma after laparoscopic pancreaticoduodenectomy Last author DOI 10.21203/rs.3.rs-2425067/v1↗
  5. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: study protocol for a multicentre randomised controlled trial. Co-author DOI 10.1136/bmjopen-2021-057128↗
  6. High Trophinin‑Associated Protein Expression and Its Role in Prognosis of Pancreatic Cancer Last author DOI 10.21203/rs.3.rs-32296/v1↗
  7. Gut Microbiota: Its Potential Roles in Pancreatic Cancer. Co-author DOI 10.3389/fcimb.2020.572492↗
  8. LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p. Last author DOI 10.1016/j.biopha.2019.108862↗
  9. Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer. Last author DOI 10.1371/journal.pone.0211291↗
  10. ITGA3 serves as a diagnostic and prognostic biomarker for pancreatic cancer. Last author DOI 10.2147/ott.s201675↗
  11. Comparison of iodine-125 seed implantation and pancreaticoduodenectomy in the treatment of pancreatic cancer. Last author DOI 10.7150/ijms.8948↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yan Jiao · 3 shared papers, 2019–2025 · strength 0.67
  2. Songyang Liu · 4 shared papers, 2014–2024 · strength 0.62
  3. Xiang Li · 1 shared paper, 2025 · strength 0.42
  4. Kai Liu · 1 shared paper, 2024 · strength 0.31
  5. Peng Xu · 1 shared paper, 2023 · strength 0.26
  6. Shutao Pan · 2 shared papers, 2022–2023 · strength 0.25
  7. Xuemin Chen · 2 shared papers, 2022–2023 · strength 0.25
  8. Jingdong Li · 2 shared papers, 2022–2023 · strength 0.25
  9. Jun Liu · 2 shared papers, 2022–2023 · strength 0.25
  10. Xianjun Yu · 2 shared papers, 2022–2023 · strength 0.25
  11. Limin Jin · 1 shared paper, 2020 · strength 0.16
  12. Quanxiao Li · 1 shared paper, 2020 · strength 0.16
  13. Renyi Qin · 1 shared paper, 2022 · strength 0.13
  14. Min Wang · 1 shared paper, 2022 · strength 0.13
  15. Taoyuan Yin · 1 shared paper, 2022 · strength 0.13
  16. Ruobing Wang · 1 shared paper, 2020 · strength 0.13
  17. Zhuo Fu · 1 shared paper, 2019 · strength 0.12
  18. Zhenxiong Zhang · 1 shared paper, 2023 · strength 0.12
  19. Hongqin Ma · 1 shared paper, 2023 · strength 0.12
  20. Yichen Tang · 1 shared paper, 2023 · strength 0.12
  21. Min Wang · 1 shared paper, 2023 · strength 0.12
  22. Pei Lu · 1 shared paper, 2023 · strength 0.12
  23. Zheng Li · 1 shared paper, 2023 · strength 0.12
  24. Chen Liu · 1 shared paper, 2023 · strength 0.12
  25. Rong Liu · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.